Nyxoah SA was incorporated in Belgium on July 15, 2009. The company is a medical technology company focused on the development and commercialization of innovative solutions for the treatment of obstructive sleep apnea (OSA), and its lead product is the Genio system. This CE certified product is a patient-centered, minimally invasive next-generation hypoglossal nerve stimulation (HGNS) therapy for the treatment of moderate to severe OSA. OSA is a common sleep-disordered breathing disorder worldwide and is associated with a higher risk of death and a variety of complications including cardiovascular disease, depression and stroke. The company's innovative technology platform is the first HGNS device to treat OSA through bilateral stimulation, designed to maintain the airway open, thereby ensuring that patients get a peaceful sleep. Nyxoah SA, which began selling the Genio system in Europe in July 2020 and is generating revenue, is currently conducting DREAM pivotal trials to support its marketing authorization application in the United States.